title: Risk of severe respiratory syncytial virus disease, identification of high risk infants and recommendations for prophylaxis with palivizumab.
authors.forename: H Cody
authors.initials: HC
authors.lastname: Meissner
authors.forename: Margaret B
authors.initials: MB
authors.lastname: Rennels
authors.forename: Larry K
authors.initials: LK
authors.lastname: Pickering
authors.forename: Caroline B
authors.initials: CB
authors.lastname: Hall
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000008:administration & dosage; D004334:Drug Administration Schedule; D006760:Hospitalization / Q000706:statistics & numerical data / Q000639:trends; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D007363:Intensive Care Units, Neonatal; D000069455:Palivizumab; D017410:Practice Guidelines as Topic; D011322:Primary Prevention / Q000379:methods; D018357:Respiratory Syncytial Virus Infections / Q000188:drug therapy / Q000517:prevention & control*; D018570:Risk Assessment
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069455:Palivizumab